From 127 AML cases, targeted next-generation sequencing revealed RAS pathway alterations (referred to as RAS+, mostly in NF1, NRAS, KRAS, PTPN11, and CBL genes) in 51 patients (40%). The gene discussed is NF1; the disease is acute myeloid leukemia.